Reuters logo
BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer
September 7, 2017 / 9:27 PM / 12 days ago

BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

Sept 8 (Reuters) - Kura Oncology Inc

* Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

* Says ‍phase 2 trial for Tipifarnib​ achieved its primary endpoint prior to completion of enrollment

* Says ‍it will continue to enroll HRAS mutant HNSCC patients​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below